Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy (2023)
Subjects: NEOPLASIAS HEPÁTICAS, CARCINOMA HEPATOCELULAR, CÉLULAS DENDRÍTICAS, IMUNOHISTOQUÍMICA
ABNT
GUTIC, Bojana et al. Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy. Clinics, v. 78, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/53969. Acesso em: 17 ago. 2024.APA
Gutic, B., Bozanovic, T., Mandic, A., Dugalic, S., Todorovic, J., Stanisavljevic, D., et al. (2023). Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy. Clinics, 78. doi:10.1016/j.clinsp.2023.100177NLM
Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, Dugalic MG, Sengul D, Detanac DA, Sengul I, Detanac D, Soares Junior JM. Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy [Internet]. Clinics. 2023 ; 78[citado 2024 ago. 17 ] Available from: https://observatorio.fm.usp.br/handle/OPI/53969Vancouver
Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, Dugalic MG, Sengul D, Detanac DA, Sengul I, Detanac D, Soares Junior JM. Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy [Internet]. Clinics. 2023 ; 78[citado 2024 ago. 17 ] Available from: https://observatorio.fm.usp.br/handle/OPI/53969